Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice (Q44057415)

29 November 2017

title

Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice (English)

1 reference

29 November 2017

1 reference

Fields PA

1

1 reference

29 November 2017

Armstrong E

2

1 reference

29 November 2017

Hagstrom JN

3

1 reference

29 November 2017

Arruda VR

4

1 reference

29 November 2017

Murphy ML

5

1 reference

29 November 2017

Farrell JP

6

1 reference

29 November 2017

High KA

7

1 reference

29 November 2017

Herzog RW

8

1 reference

29 November 2017

publication date

1 March 2001

1 reference

29 November 2017

1 reference

29 November 2017

volume

8

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

354-361

1 reference

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Efficient lentiviral transduction of liver requires cell cycling in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Adeno-associated virus vectors can be efficiently produced without helper virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

Interleukin-10 expression is autoregulated at the transcriptional level in human and murine kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

The incidence of factor VIII inhibitors in patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Problems and prospects in gene therapy for hemophilia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301409

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301409

1 reference

29 November 2017

1 reference